S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.52 (-0.07%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.92 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.39 (+1.12%)
T   17.62 (+0.40%)
F   13.29 (+1.76%)
MU   117.81 (-1.12%)
CGC   8.54 (-10.58%)
GE   175.85 (-2.37%)
DIS   122.42 (+1.19%)
AMC   3.72 (-14.29%)
PFE   27.80 (+0.07%)
PYPL   66.99 (+0.63%)
XOM   116.20 (+1.07%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.52 (-0.07%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.92 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.39 (+1.12%)
T   17.62 (+0.40%)
F   13.29 (+1.76%)
MU   117.81 (-1.12%)
CGC   8.54 (-10.58%)
GE   175.85 (-2.37%)
DIS   122.42 (+1.19%)
AMC   3.72 (-14.29%)
PFE   27.80 (+0.07%)
PYPL   66.99 (+0.63%)
XOM   116.20 (+1.07%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.52 (-0.07%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.92 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.39 (+1.12%)
T   17.62 (+0.40%)
F   13.29 (+1.76%)
MU   117.81 (-1.12%)
CGC   8.54 (-10.58%)
GE   175.85 (-2.37%)
DIS   122.42 (+1.19%)
AMC   3.72 (-14.29%)
PFE   27.80 (+0.07%)
PYPL   66.99 (+0.63%)
XOM   116.20 (+1.07%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.52 (-0.07%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.92 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.39 (+1.12%)
T   17.62 (+0.40%)
F   13.29 (+1.76%)
MU   117.81 (-1.12%)
CGC   8.54 (-10.58%)
GE   175.85 (-2.37%)
DIS   122.42 (+1.19%)
AMC   3.72 (-14.29%)
PFE   27.80 (+0.07%)
PYPL   66.99 (+0.63%)
XOM   116.20 (+1.07%)
NASDAQ:LUCD

Lucid Diagnostics (LUCD) Stock Price, News & Analysis

$0.93
-0.06 (-6.06%)
(As of 03:51 PM ET)
Today's Range
$0.90
$1.00
50-Day Range
$0.99
$1.45
52-Week Range
$0.90
$1.85
Volume
618,859 shs
Average Volume
123,756 shs
Market Capitalization
$44.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.75

Lucid Diagnostics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
180.6% Upside
$2.75 Price Target
Short Interest
Healthy
2.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.01mentions of Lucid Diagnostics in the last 14 days
Based on 14 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.60 out of 5 stars

Medical Sector

672nd out of 939 stocks

Surgical & Medical Instruments Industry

69th out of 98 stocks

LUCD stock logo

About Lucid Diagnostics Stock (NASDAQ:LUCD)

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma (EAC). It offers EsoCheck, a cell collection device to prevent EAC deaths; and EsoGuard, an Esophageal DNA Test. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

LUCD Stock Price History

LUCD Stock News Headlines

AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Q4 2023 Lucid Diagnostics Inc Earnings Call
Lucid Diagnostics (LUCD) Set to Announce Earnings on Tuesday
The 3 Most Undervalued Penny Stocks to Buy in December
Lucid Diagnostics Inc LUCD
See More Headlines
Receive LUCD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lucid Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/26/2024
Today
3/28/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:LUCD
Fax
N/A
Employees
2,021
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.75
High Stock Price Target
$3.00
Low Stock Price Target
$2.50
Potential Upside/Downside
+177.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-56,170,000.00
Net Margins
-2,169.07%
Pretax Margin
-2,169.11%

Debt

Sales & Book Value

Annual Sales
$2.43 million
Book Value
$0.59 per share

Miscellaneous

Free Float
42,523,000
Market Cap
$47.76 million
Optionable
No Data
Beta
1.73
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Lishan Aklog M.D. (Age 58)
    Chairman & CEO
  • Mr. Shaun M. O'Neill M.B.A. (Age 41)
    President & COO
  • Mr. Dennis M. McGrath C.P.A. (Age 67)
    Chief Financial Officer
  • Dr. Sanford D. Markowitz M.D.
    Ph.D., Cofounder & Strategic Advisor, Member of the Medical Advisor Board
  • Dr. Joseph Willis M.D.
    Cofounder, Strategic Advisor & Member of Medical Advisory Board
  • Dr. Amitabh Chak M.D.
    Cofounder, Strategic Advisor & Member of Medical Advisory Board
  • Richard D. Yazbeck
    Chief Technology Officer
  • Dr. Suman M. Verma M.D.
    Ph.D., Chief Scientific Officer
  • Dr. Brian J. deGuzman M.D. (Age 59)
    Chief Compliance Officer
  • Mr. Michael Adam Gordon (Age 50)
    General Counsel & Secretary

LUCD Stock Analysis - Frequently Asked Questions

Should I buy or sell Lucid Diagnostics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lucid Diagnostics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LUCD shares.
View LUCD analyst ratings
or view top-rated stocks.

What is Lucid Diagnostics' stock price target for 2024?

2 brokers have issued 12 month target prices for Lucid Diagnostics' shares. Their LUCD share price targets range from $2.50 to $3.00. On average, they expect the company's stock price to reach $2.75 in the next year. This suggests a possible upside of 180.6% from the stock's current price.
View analysts price targets for LUCD
or view top-rated stocks among Wall Street analysts.

How have LUCD shares performed in 2024?

Lucid Diagnostics' stock was trading at $1.41 at the beginning of 2024. Since then, LUCD stock has decreased by 30.5% and is now trading at $0.9799.
View the best growth stocks for 2024 here
.

When is Lucid Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our LUCD earnings forecast
.

How were Lucid Diagnostics' earnings last quarter?

Lucid Diagnostics Inc. (NASDAQ:LUCD) released its quarterly earnings results on Tuesday, March, 26th. The company reported ($0.26) earnings per share (EPS) for the quarter. The business earned $1.04 million during the quarter. Lucid Diagnostics had a negative trailing twelve-month return on equity of 8,334.14% and a negative net margin of 2,169.07%. During the same quarter last year, the firm earned ($0.22) earnings per share.

When did Lucid Diagnostics IPO?

Lucid Diagnostics (LUCD) raised $75 million in an IPO on Thursday, October 14th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share.

Who are Lucid Diagnostics' major shareholders?

Lucid Diagnostics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Luminus Management LLC (1.73%), Nantahala Capital Management LLC (0.34%) and Virtu Financial LLC (0.05%).
View institutional ownership trends
.

How do I buy shares of Lucid Diagnostics?

Shares of LUCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LUCD) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners